<article article-type="case-study" dtd-version="1.4" id="iju570150" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">IJU Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">IJU Case Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3875</journal-id><journal-id journal-id-type="pmc-domain">ijucaserep</journal-id><journal-id journal-id-type="publisher-id">IJU5</journal-id><journal-title-group><journal-title>IJU Case Reports</journal-title></journal-title-group><issn pub-type="epub">2577-171X</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12907570</article-id><article-id pub-id-type="pmcid-ver">PMC12907570.1</article-id><article-id pub-id-type="pmcaid">12907570</article-id><article-id pub-id-type="pmcaiid">12907570</article-id><article-id pub-id-type="pmid">41704727</article-id><article-id pub-id-type="doi">10.1002/iju5.70150</article-id><article-id pub-id-type="publisher-id">IJU570150</article-id><article-id pub-id-type="other">3977006</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Early Recognition of Immune‐Related Hepatitis During Avelumab Maintenance Therapy for Urothelial Carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="iju570150-cr-0001"><name name-style="western"><surname>Iwama</surname><given-names initials="Y">Yuka</given-names></name><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0009-0001-6005-9210</contrib-id><xref ref-type="aff" rid="iju570150-aff-0001">
<sup>1</sup>
</xref><address><email>iwama.yuka.300@gmail.com</email></address></contrib><contrib contrib-type="author" id="iju570150-cr-0002"><name name-style="western"><surname>Sano</surname><given-names initials="T">Tomoyasu</given-names></name><xref ref-type="aff" rid="iju570150-aff-0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" id="iju570150-cr-0003"><name name-style="western"><surname>Sano</surname><given-names initials="Y">Yuta</given-names></name><xref ref-type="aff" rid="iju570150-aff-0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" id="iju570150-cr-0004"><name name-style="western"><surname>Kimura</surname><given-names initials="T">Tomokazu</given-names></name><xref ref-type="aff" rid="iju570150-aff-0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" id="iju570150-cr-0005"><name name-style="western"><surname>Naito</surname><given-names initials="Y">Yushi</given-names></name><xref ref-type="aff" rid="iju570150-aff-0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" id="iju570150-cr-0006"><name name-style="western"><surname>Inoue</surname><given-names initials="S">Satoshi</given-names></name><xref ref-type="aff" rid="iju570150-aff-0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" id="iju570150-cr-0007"><name name-style="western"><surname>Matsuo</surname><given-names initials="K">Kazuna</given-names></name><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-8574-2932</contrib-id><xref ref-type="aff" rid="iju570150-aff-0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" id="iju570150-cr-0008"><name name-style="western"><surname>Ishida</surname><given-names initials="S">Shohei</given-names></name><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-9338-4781</contrib-id><xref ref-type="aff" rid="iju570150-aff-0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" id="iju570150-cr-0009"><name name-style="western"><surname>Matsukawa</surname><given-names initials="Y">Yoshihisa</given-names></name><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-7823-2600</contrib-id><xref ref-type="aff" rid="iju570150-aff-0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" id="iju570150-cr-0010"><name name-style="western"><surname>Akamatsu</surname><given-names initials="S">Shusuke</given-names></name><xref ref-type="aff" rid="iju570150-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="iju570150-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Urology</named-content>
<institution>Nagoya University</institution>
<city>Nagoya</city>
<named-content content-type="country-part">Aichi</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Yuka Iwama (<email>iwama.yuka.300@gmail.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>2</month><year>2026</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2026</year></pub-date><volume>9</volume><issue seq="120">2</issue><issue-id pub-id-type="pmc-issue-id">506263</issue-id><issue-id pub-id-type="doi">10.1002/iju5.v9.2</issue-id><elocation-id>e70150</elocation-id><history><date date-type="rev-recd"><day>10</day><month>1</month><year>2026</year></date><date date-type="received"><day>27</day><month>10</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>17</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-18 15:25:12.493"><day>18</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2026 The Author(s). <italic toggle="yes">IJU Case Reports</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Urological Association.</copyright-statement><license><ali:license_ref content-type="ccbyncndlicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="IJU5-9-e70150.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><self-uri content-type="pdf" xlink:href="file:IJU5-9-e70150.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><title>ABSTRACT</title><sec id="iju570150-sec-0001"><title>Introduction</title><p>Avelumab is recommended as maintenance therapy for advanced urothelial carcinoma after platinum chemotherapy; however, immune‐related adverse events can be severe and refractory.</p></sec><sec id="iju570150-sec-0002"><title>Case Presentation</title><p>A 79‐year‐old male developed immune‐related hepatitis during avelumab maintenance therapy following gemcitabine plus carboplatin for metastatic recurrent urothelial carcinoma. Despite discontinuation of avelumab and treatment with high‐dose corticosteroids, mycophenolate mofetil, and plasma exchange, liver failure progressed, leading to death on day 106.</p></sec><sec id="iju570150-sec-0003"><title>Conclusion</title><p>Hepatic irAEs during avelumab therapy are rare but potentially fatal. Early recognition and aggressive multidisciplinary management are essential to improve outcomes.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="iju570150-kwd-0001">avelumab</kwd><kwd id="iju570150-kwd-0002">drug‐induced liver injury</kwd><kwd id="iju570150-kwd-0003">immune‐related hepatitis</kwd><kwd id="iju570150-kwd-0004">urothelial carcinoma</kwd></kwd-group><counts><fig-count count="4"/><table-count count="0"/><page-count count="4"/><word-count count="1700"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.8 mode:remove_FC converted:16.02.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation id="iju570150-cit-1001" publication-type="journal">
<string-name name-style="western">
<given-names>Y.</given-names>
<surname>Iwama</surname>
</string-name>, <string-name name-style="western">
<given-names>T.</given-names>
<surname>Sano</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Sano</surname>
</string-name>, et al., “<article-title>Early Recognition of Immune‐Related Hepatitis During Avelumab Maintenance Therapy for Urothelial Carcinoma</article-title>,” <source>IJU Case Reports</source>
<volume>9</volume>, no. <issue>2</issue> (<year>2026</year>): <elocation-id>e70150</elocation-id>, <pub-id pub-id-type="doi">10.1002/iju5.70150</pub-id>.</mixed-citation>
</p></notes></front><body id="iju570150-body-0001"><p>
<boxed-text content-type="box" id="iju570150-blkfxd-0001" orientation="portrait" position="anchor"><caption><title>Keynote</title></caption><p>Immune‐related hepatitis occurring during avelumab treatment is rare but potentially fatal. Treatment involves immediate discontinuation of the immune checkpoint inhibitor and initiation of high‐dose corticosteroids. Some patients may not respond to treatment, making proactive multidisciplinary management crucial for improving prognosis.</p></boxed-text>
</p><sec id="iju570150-sec-0006"><label>1</label><title>Introduction</title><p>Avelumab, a PD‐L1 inhibitor, is approved as maintenance therapy for patients with advanced urothelial carcinoma without disease progression after platinum‐based chemotherapy. The JAVELIN Bladder 100 trial demonstrated a significant survival benefit; however, immune‐related adverse events (irAEs) remain a major concern. Although hepatic irAEs are relatively uncommon, some can be life‐threatening. We report a fatal case of immune‐related hepatitis that occurred during avelumab maintenance therapy. Grade ≥ 3 immune‐related adverse events occur in approximately 19.5% of patients, although hepatic events are relatively uncommon [<xref ref-type="bibr" rid="iju570150-bib-0001">1</xref>].</p></sec><sec id="iju570150-sec-0007"><label>2</label><title>Case Presentation</title><p>A 79‐year‐old Japanese male with a past medical history of hypertension and angina presented with gross hematuria. Computed tomography (CT) revealed thickening of the right renal pelvis and ureteral wall (Figure <xref ref-type="fig" rid="iju570150-fig-0001">1</xref>). Urinary cytology showed atypical urothelial cells, and ureteroscopic biopsy confirmed urothelial carcinoma. No distant metastases were detected, and the clinical stage was cT1N0M0. The patient underwent robot‐assisted nephroureterectomy. Based on the preoperative clinical stage, lymph node dissection was not performed. Pathology revealed invasive urothelial carcinoma, G3, pT4, with lymphatic invasion and venous invasion, and tumor extension into the renal parenchyma and perirenal adipose tissue.</p><fig fig-type="FIGURE" id="iju570150-fig-0001" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>CT showing thickening of the right ureteral wall and renal pelvis, consistent with the primary urothelial carcinoma site.</p></caption><graphic id="jats-graphic-1" orientation="portrait" position="anchor" xlink:href="IJU5-9-e70150-g003.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>Two months later, CT showed lymph node metastases (Figure <xref ref-type="fig" rid="iju570150-fig-0002">2</xref>), and combination chemotherapy with gemcitabine plus carboplatin was initiated. After four cycles, avelumab (10 mg/kg every 2 weeks) was started as maintenance therapy. On Day 71, CTCAE grade 1 elevation of alkaline phosphatase (ALP) was noted. At that time, AST, ALT, and bilirubin levels remained within normal limits, indicating isolated ALP elevation. By Day 92, aspartate aminotransferase (AST) and ALP elevation had worsened to grade 2, and alanine aminotransferase (ALT) to grade 1. Avelumab was discontinued, and ursodeoxycholic acid was administered. On day 99, AST and ALP elevation reached grade 3 and ALT grade 2; CT demonstrated hepatomegaly with mottled enhancement (Figure <xref ref-type="fig" rid="iju570150-fig-0003">3</xref>). The patient was admitted to the intensive care unit (ICU) with a diagnosis of acute liver failure.</p><fig fig-type="FIGURE" id="iju570150-fig-0002" orientation="portrait" position="float"><label>FIGURE 2</label><caption><p>CT showing enlarged para‐aortic lymph nodes, indicating metastatic progression two months after surgery.</p></caption><graphic id="jats-graphic-3" orientation="portrait" position="anchor" xlink:href="IJU5-9-e70150-g001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig fig-type="FIGURE" id="iju570150-fig-0003" orientation="portrait" position="float"><label>FIGURE 3</label><caption><p>CT showing hepatomegaly and mottled enhancement of the liver parenchyma, suggestive of immune‐related hepatitis.</p></caption><graphic id="jats-graphic-5" orientation="portrait" position="anchor" xlink:href="IJU5-9-e70150-g004.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>Steroid pulse therapy (methylprednisolone 1000 mg/day for 3 days) was initiated, followed by methylprednisolone 60 mg/day, mycophenolate mofetil 2 g/day, and plasma exchange performed three times. Liver function transiently improved; however, it subsequently deteriorated. Viral hepatitis and liver metastases were excluded. Liver biopsy was not performed due to coagulopathy. The patient died of liver failure on day 106 (Figure <xref ref-type="fig" rid="iju570150-fig-0004">4</xref>).</p><fig fig-type="FIGURE" id="iju570150-fig-0004" orientation="portrait" position="float"><label>FIGURE 4</label><caption><p>Trend of AST, ALT, and ALP levels over time, with corresponding immunosuppressive treatments including corticosteroids, mycophenolate mofetil, and plasma exchange. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ICU, intensive care unit; mPSL, methylprednisolone; TAZ/PIPC, tazobactam/piperacillin.</p></caption><graphic id="jats-graphic-7" orientation="portrait" position="anchor" xlink:href="IJU5-9-e70150-g002.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></sec><sec id="iju570150-sec-0008" sec-type="discussion"><label>3</label><title>Discussion</title><p>Avelumab generally exhibits a favorable safety profile among PD‐L1 inhibitors, with fatal adverse events reported in approximately 0.9% of cases [<xref ref-type="bibr" rid="iju570150-bib-0002">2</xref>, <xref ref-type="bibr" rid="iju570150-bib-0003">3</xref>] Nevertheless, immune checkpoint inhibitor–induced liver injury (ICI‐DILI) remains a clinically significant challenge. Hepatic irAEs typically occur within 6–14 weeks after initiating PD‐1/PD‐L1 inhibitors, consistent with the present case.</p><p>According to the 2021 ASCO guideline update, management of grade ≥ 3 ICI‐DILI includes immediate discontinuation of the immune checkpoint inhibitor and initiation of high‐dose corticosteroids. If liver function does not improve, mycophenolate mofetil or other immunosuppressants should be added [<xref ref-type="bibr" rid="iju570150-bib-0004">4</xref>]. In our case, both were administered, yet the patient's liver function remained refractory to treatment.</p><p>Recent reports indicate that the histological pattern of ICI‐induced hepatitis affects treatment response: hepatocellular‐type injury tends to respond to corticosteroids, whereas cholestatic‐type injury is often steroid‐resistant [<xref ref-type="bibr" rid="iju570150-bib-0005">5</xref>]. Based on laboratory findings and R ratio, our patient likely had a cholestatic pattern, which may explain the poor response. Early recognition and timely escalation of immunosuppressive therapy are important. Despite plasma exchange, the outcome remained poor.</p><p>The 2025 NCCN guideline emphasizes multidisciplinary coordination and early escalation of immunosuppressive therapy for refractory cases [<xref ref-type="bibr" rid="iju570150-bib-0006">6</xref>]. Clinicians should remain vigilant for hepatic irAEs. Multidisciplinary collaboration involving hepatology, oncology, and critical care teams is essential for optimizing outcomes in severe cases. Emerging salvage approaches, such as artificial liver support systems, have shown promise in selected steroid‐refractory cases, although evidence remains limited. Furthermore, the development of predictive biomarkers to identify patients at risk for steroid‐refractory ICI‐DILI is urgently needed to guide early intervention strategies.</p><p>R ratio was calculated as (ALT/ULN) ÷ (ALP/ULN), where values ≥ 5 indicate a hepatocellular pattern, ≤ 2 indicate a cholestatic pattern, and 2–5 indicate a mixed pattern.</p><p>This case underscores the importance of early recognition and timely escalation of immunosuppressive therapy.</p><p>Avelumab maintenance remains a key option after platinum‐based chemotherapy; however, in the current treatment landscape for metastatic urothelial carcinoma, the combination of enfortumab vedotin (EV) and pembrolizumab has become the new standard of care, making the management of irAEs increasingly critical. Although there are no substantial reports of autoimmune hepatitis with EV + pembrolizumab therapy, grade 3 or higher AST elevation has been reported in 5% of cases [<xref ref-type="bibr" rid="iju570150-bib-0007">7</xref>].</p><p>Clinicians should remain vigilant for hepatic irAEs, especially those presenting with atypical or rapidly progressive features. Even low‐grade elevations in liver enzymes, we should prompt weekly monitoring and early consultation with a hepatologist if progressive or involving multiple parameters.</p><p>Furthermore, recent evidence suggests that PD‐L1 inhibitors, such as avelumab, may have a lower incidence of severe immune‐related adverse events compared to PD‐1 inhibitors (nivolumab, pembrolizumab). This difference is hypothesized to result from the preservation of PD‐1/PD‐L2 interaction, which may maintain partial immune checkpoint signaling and self‐tolerance. Wang et al. reported in a meta‐analysis that PD‐L1 inhibitors were associated with a lower mean incidence of grade ≥ 3 adverse events compared with PD‐1 inhibitors [<xref ref-type="bibr" rid="iju570150-bib-0008">8</xref>]. Although the clinical significance of this observation remains unclear, these findings support the overall favorable safety profile of PD‐L1 inhibitors. Our case, therefore, represents a rare but important exception that underscores the need for vigilance despite the generally reassuring safety data.</p></sec><sec id="iju570150-sec-0009" sec-type="conclusions"><label>4</label><title>Conclusion</title><p>Previous reports of avelumab maintenance therapy have described four treatment‐related grade 5 events: nephritis, pneumonitis, sepsis, and cerebral infarction; notably, fatal hepatic irAEs have not been documented [<xref ref-type="bibr" rid="iju570150-bib-0001">1</xref>, <xref ref-type="bibr" rid="iju570150-bib-0009">9</xref>].</p><p>This case highlights that immune‐related hepatitis during avelumab maintenance therapy, though rare, can be fatal. Early recognition, prompt discontinuation of therapy, and aggressive multidisciplinary management are crucial for improving outcomes.</p></sec><sec id="iju570150-sec-0011"><title>Ethics Statement</title><p>This study was approved by the Institutional Review Board of Nagoya University (approval number 2016‐0474‐9).</p></sec><sec id="iju570150-sec-0012" sec-type="conclusions"><title>Consent</title><p>Written informed consent was obtained from the patient for publication of this report.</p></sec><sec id="iju570150-sec-0010" sec-type="COI-statement"><title>Conflicts of Interest</title><p>Shusuke Akamatsu and Shohei Ishida are the Editorial Board member of <italic toggle="yes">International Journal of Urology</italic> Case Report and the co‐authors of this article. To minimize bias, they were excluded from all editorial decision‐making related to the acceptance of this article for publication.</p></sec></body><back><sec id="iju570150-sec-0014" sec-type="data-availability"><title>Data Availability Statement</title><p>Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.</p></sec><ref-list content-type="cited-references" id="iju570150-bibl-0001"><title>References</title><ref id="iju570150-bib-0001"><label>1</label><mixed-citation id="iju570150-cit-0001" publication-type="journal">
<string-name name-style="western">
<given-names>T.</given-names>
<surname>Powles</surname>
</string-name>, <string-name name-style="western">
<given-names>S. H.</given-names>
<surname>Park</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Caserta</surname>
</string-name>, et al., “<article-title>Avelumab First‐Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow‐Up</article-title>,” <source>Journal of Clinical Oncology</source>
<volume>41</volume>, no. <issue>19</issue> (<year>2023</year>): <fpage>3486</fpage>–<lpage>3492</lpage>.<pub-id pub-id-type="pmid">37071838</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1200/JCO.22.01792</pub-id><pub-id pub-id-type="pmcid">PMC10306435</pub-id></mixed-citation></ref><ref id="iju570150-bib-0002"><label>2</label><mixed-citation id="iju570150-cit-0002" publication-type="journal">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Guru</surname>
</string-name>, <string-name name-style="western">
<given-names>G.</given-names>
<surname>Petros</surname>
</string-name>, <string-name name-style="western">
<given-names>L.</given-names>
<surname>Yushun</surname>
</string-name>, et al., “<article-title>Immune‐Related Adverse Events With PD‐1 Versus PD‐L1 Inhibitors: A Meta‐Analysis of 8730 Patients From Clinical Trials</article-title>,” <source>Future Oncology</source>
<volume>17</volume>, no. <issue>19</issue> (<year>2021</year>): <fpage>2545</fpage>–<lpage>2558</lpage>.<pub-id pub-id-type="pmid">33783228</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.2217/fon-2020-1222</pub-id></mixed-citation></ref><ref id="iju570150-bib-0003"><label>3</label><mixed-citation id="iju570150-cit-0003" publication-type="journal">
<string-name name-style="western">
<given-names>W.</given-names>
<surname>Xuewen</surname>
</string-name>, <string-name name-style="western">
<given-names>W.</given-names>
<surname>Shijie</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Yaying</surname>
</string-name>, et al., “<article-title>Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta‐Analysis</article-title>,” <source>Frontiers in Pharmacology</source>
<volume>11</volume> (<year>2020</year>): <elocation-id>5</elocation-id>.<pub-id pub-id-type="pmid">32076409</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fphar.2020.00005</pub-id><pub-id pub-id-type="pmcid">PMC7006642</pub-id></mixed-citation></ref><ref id="iju570150-bib-0004"><label>4</label><mixed-citation id="iju570150-cit-0004" publication-type="journal">
<string-name name-style="western">
<given-names>J. S.</given-names>
<surname>Bryan</surname>
</string-name>, <string-name name-style="western">
<given-names>N.</given-names>
<surname>Jarushka</surname>
</string-name>, and <string-name name-style="western">
<given-names>D. S.</given-names>
<surname>Bianca</surname>
</string-name>, “<article-title>Management of Immune‐Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update</article-title>,” <source>Journal of Clinical Oncology</source>
<volume>39</volume>, no. <issue>36</issue> (<year>2021</year>): <fpage>4073</fpage>–<lpage>4086</lpage>.<pub-id pub-id-type="pmid">34724392</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1200/JCO.21.01440</pub-id></mixed-citation></ref><ref id="iju570150-bib-0005"><label>5</label><mixed-citation id="iju570150-cit-0005" publication-type="journal">
<string-name name-style="western">
<given-names>P.</given-names>
<surname>Lucia</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Kennie</surname>
</string-name>, <string-name name-style="western">
<given-names>T.</given-names>
<surname>Benoit</surname>
</string-name>, et al., “<article-title>Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study</article-title>,” <source>Journal of Clinical Medicine</source>
<volume>12</volume>, no. <issue>11</issue> (<year>2023</year>): <elocation-id>3751</elocation-id>.<pub-id pub-id-type="pmid">37297945</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/jcm12113751</pub-id><pub-id pub-id-type="pmcid">PMC10253512</pub-id></mixed-citation></ref><ref id="iju570150-bib-0006"><label>6</label><mixed-citation id="iju570150-cit-0006" publication-type="miscellaneous">
<collab collab-type="authors">National Comprehensive Cancer Network</collab>
, <article-title>“NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Management of Immunotherapy‐Related Toxicities,”</article-title> Version 1.2025.</mixed-citation></ref><ref id="iju570150-bib-0007"><label>7</label><mixed-citation id="iju570150-cit-0007" publication-type="journal">
<string-name name-style="western">
<given-names>B.</given-names>
<surname>Blaine</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Asia</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Hiba</surname>
</string-name>, et al., “<article-title>Managing Potential Adverse Events During Treatment With Enfortumab Vedotin + Pembrolizumab in Patients With Advanced Urothelial Cancer</article-title>,” <source>Frontiers in Oncology</source>
<volume>22</volume>, no. <issue>14</issue> (<year>2024</year>): <elocation-id>1326715</elocation-id>.<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fonc.2024.1326715</pub-id><pub-id pub-id-type="pmcid">PMC11071165</pub-id><pub-id pub-id-type="pmid">38711854</pub-id></mixed-citation></ref><ref id="iju570150-bib-0008"><label>8</label><mixed-citation id="iju570150-cit-0008" publication-type="journal">
<string-name name-style="western">
<given-names>W.</given-names>
<surname>Yucai</surname>
</string-name>, <string-name name-style="western">
<given-names>Z.</given-names>
<surname>Shouhao</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Fang</surname>
</string-name>, et al., “<article-title>Treatment‐Related Adverse Events of PD‐1 and PD‐L1 Inhibitors in Clinical Trials: A Systematic Review and Meta‐Analysis</article-title>,” <source>JAMA Oncology</source>
<volume>15</volume>, no. <issue>7</issue> (<year>2019</year>): <fpage>1008</fpage>–<lpage>1019</lpage>.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1001/jamaoncol.2019.0393</pub-id><pub-id pub-id-type="pmcid">PMC6487913</pub-id><pub-id pub-id-type="pmid">31021376</pub-id></mixed-citation></ref><ref id="iju570150-bib-0009"><label>9</label><mixed-citation id="iju570150-cit-0009" publication-type="journal">
<string-name name-style="western">
<given-names>E.</given-names>
<surname>Jennifer</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Navkirat</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Sonia</surname>
</string-name>, et al., “<article-title>Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes</article-title>,” <source>Cancer Management and Research</source>
<volume>22</volume>, no. <issue>14</issue> (<year>2022</year>): <fpage>729</fpage>–<lpage>738</lpage>.<pub-id assigning-authority="pmc" pub-id-type="doi">10.2147/CMAR.S227323</pub-id><pub-id pub-id-type="pmcid">PMC8882657</pub-id><pub-id pub-id-type="pmid">35237074</pub-id></mixed-citation></ref></ref-list></back></article>